Protection of factor Xa from neutralization by the heparin-antithrombin complex.

No abstract is available for this paper.

• Publication year

  1983

• Venue

  Journal of Clinical Investigation

• Publication date

  1983-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1172/JCI110891PMID 6222069PMCID PMC437002
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex.

  1982cited by this paper
• Heparin with two binding sites for antithrombin or platelet factor 4.

  1982cited by this paper
• Coordinate binding of factor Va and factor Xa to the unstimulated platelet.

  1981cited by this paper
• Relationship between platelet secretion and prothrombin cleavage in native whole blood.

  1981cited by this paper
• The role of phospholipids and factor Va in the prothrombinase complex.

  1980cited by this paper
• Factor Va-dependent binding of factor Xa to human platelets.

  1980cited by this paper
• Isolated deficiency of platelet procoagulant activity.

  1979cited by this paper
• The effects of phospholipid and factor Va on the inhibition of factor Xa by antithrombin III.

  1979cited by this paper
• Deficiency of factor Xa-factor Va binding sites on the platelets of a patient with a bleeding disorder.

  1979cited by this paper
• The isolation and characterization of a specific antibody population directed against the prothrombin activation fragments F2 and F1 + 2.

  1979cited by this paper
• Interaction of coagulation factor V and factor Va with platelets.

  1979cited by this paper
• Binding of bovine coagulation factor Xa to platelets.

  1978cited by this paper
• Properties of the factor Xa binding site on human platelets.

  1978cited by this paper
• Interaction of coagulation factor Xa with human platelets.

  1977cited by this paper
• Alpha 2-macroglobulin and antithrombin-heparin cofactor: modulators of hemostatic and inflammatory reactions. Alpha 2-macroglobulin.

  1976cited by this paper
• Statistical characterization of the random errors in the radioimmunoassay dose--response variable.

  1976cited by this paper
• Anticoagulant activity of heparin: Separation of high‐activity and low‐activity heparin species by affinity chromatography on immobilized antithrombin

  1976cited by this paper
• The separation of active and inactive forms of heparin.

  1976cited by this paper
• The Conversion of Prothrombin to Thrombin: The Function of the Propiece of Prothrombin

  1975cited by this paper
• Effect of Heparin on the Neutralization of Factor Xa and Thrombin by the Plasma Alpha-2-Globulin Inhibitor

  1975cited by this paper
• Statistical quality control and routine data processing for radioimmunoassays and immunoradiometric assays.

  1974cited by this paper
• A plausible mechanism for prothrombin activation by factor Xa, factor Va, phospholipid, and calcium ions.

  1974cited by this paper
• Factor-Xa inactivation by antithrombin. 3. Evidence for biological stabilization of factor Xa by factor V-phospholipid complex.

  1973cited by this paper
• Studies on fractionated heparin.

  1961cited by this paper

• Thrombophilia Screening: Not So Straightforward

  2024cites this paper
• Antiviral anticoagulation

  2020cites this paper
• Blood coagulation dissected.

  2018cites this paper
• New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism

  2017cites this paper
• Low molecular weight heparin

  2014cites this paper
• Is the antithrombotic effect of sulfated galactans independent of serpin?

  2014cites this paper
• Covalently linking heparin to antithrombin enhances prothrombinase inhibition on activated platelets

  2013cites this paper
• Inhibition of the prothrombinase complex on red blood cells by heparin and covalent antithrombin-heparin complex.

  2013cites this paper
• Mechanism of inhibition of the prothrombinase complex by a covalent antithrombin-heparin complex.

  2012cites this paper
• Novel function of coagulation factor Xa : conversion into a clot-dissolving cofactor

  2011cites this paper
• Bivalirudin utilization in cardiac surgery: shifting anticoagulation from indirect to direct thrombin inhibition

  2011cites this paper
• Antithrombin deficiency and its laboratory diagnosis

  2010cites this paper
• Biological Function of Glycosaminoglycans

  2008cites this paper
• Effektivität und Sicherheit einer kombinierten blutverdünnenden Medikation bei Stentangioplastien der Arteria carotis

  2007cites this paper
• 13 Thrombosis and Thrombin

  2007cites this paper
• Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome.

  2005cites this paper
• Interventional Cardiovascular Pharmacotherapy

  2005cites this paper
• Biochemical and Pharmacologic Rationale for Synthetic Heparin Polysaccharides

  2005cites this paper
• Novel antithrombotic strategies for the treatment of coronary artery thrombosis: A critical appraisal

  2005cites this paper
• Laboratory measurement of thrombin activity—What every clinician scientist needs to know

  2005cites this paper
• Clotting for the clinician: An overview of thrombosis and antithrombotic therapy

  2005cites this paper
• Monitoring of immunotherapy with cytokines or monoclonal antibodies

  2004cites this paper
• Adjunctive Pharmacologic Treatment: Focus on the Development of Low Molecular Weight Heparins

  2004cites this paper
• Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma

  2004cites this paper
• Current anticoagulant therapy--unmet clinical needs.

  2003cites this paper
• The Long-Term Clinical Outcomes of Low Molecular Weight Heparin Combined with Platelet Glycoprotein IIb/IIIa Inhibitor in Patients with Acute Coronary Syndrome

  2003cites this paper
• Factor Xa is highly protected from antithrombin–fondaparinux and antithrombin–enoxaparin when incorporated into the prothrombinase complex

  2003cites this paper
• Direct versus indirect thrombin inhibition in percutaneous coronary intervention.

  2002cites this paper
• Antithrombin deficiency: issues in laboratory diagnosis.

  2002cites this paper
• Overview of anticoagulant drugs for the future.

  2002cites this paper
• Bivalirudin: a direct thrombin inhibitor.

  2002cites this paper
• Heparin Heparin has been used to prevent intravascular thrombosis and clotting on the surface of equipment used during percutaneous coronary interventions

  2002cites this paper
• Antithrombotic agents in the treatment of severe sepsis

  2002cites this paper
• Direct thrombin inhibitors for percutaneous coronary intervention in the current era of platelet glycoprotein IIb/IIIa inhibition.

  2002cites this paper
• Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention

  2001cites this paper
• Antithrombotic effects of a synthetic inhibitor of activated factor X, JTV-803, in animals.

  2001cites this paper
• Pharmacological Treatments for Thrombotic Diseases

  2001cites this paper
• Emerging anticoagulant and thrombolytic drugs

  2001cites this paper
• Pharmacological characterization of a novel factor Xa inhibitor, FXV673.

  2001cites this paper
• Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex.

  2001cites this paper
• Coagulation system and platelets are fully activated in uncomplicated sepsis

  2000cites this paper
• In vitro characterization of a novel factor Xa inhibitor, RPR 130737.

  2000cites this paper
• In Vivo Thrombin Generation and Activity During and After Intravenous Infusion of Heparin or Recombinant Hirudin in Patients With Unstable Angina Pectoris

  2000cites this paper
• Assessment of the anti-Xa activities of Low Molecular Weight Heparins in Patients with Acute Coronary Syndrome

  2000cites this paper
• Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease.

  2000cites this paper
• Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.

  2000cites this paper
• Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis.

  2000cites this paper
• New Thrombolytics, Anticoagulants, and Platelet Antagonists: The Future of Clinical Practice

  1999cites this paper
• Activation markers of coagulation.

  1999cites this paper
• Vasoflux, a new anticoagulant with a novel mechanism of action.

  1999cites this paper
• Mechanisms of antithrombotic drugs.

  1999cites this paper
• Switching serine protease specificity

  1998cites this paper
• Prolonged activation of prothrombin on the vascular wall after arterial injury.

  1998cites this paper
• The new anticoagulants: new opportunities, new issues.

  1998cites this paper
• College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: Future Directions

  1998cites this paper
• Increase in Thrombin Generation after Coronary Thrombolysis with rt-PA or Streptokinase with Simultaneous Heparin versus Heparin Alone

  1998cites this paper
• Assessment of Thrombin Inhibitor Efficacy in a Novel Rabbit Model of Simultaneous Arterial and Venous Thrombosis

  1998cites this paper
• New therapies for unstable angina and non-Q-wave myocardial infarction: recent clinical trials.

  1998cites this paper
• Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin.

  1998cites this paper
• Systemic Thrombin Generation and Activity Resistant to Low Molecular Weight Heparin Administered Prior to Streptokinase in Patients with Acute Myocardial Infarction

  1997cites this paper
• Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration.

  1997cites this paper
• Chapter 8. Antithrombotics/Serine Proteases

  1997cites this paper
• Editor's note: Low molecular weight heparin for acute ischemic heart disease

  1997cites this paper
• State-of-the-Art Review: The Preclinical and Clinical Pharmacology of Novastan (Argatroban): A Small-Molecule, Direct Thrombin Inhibitor

  1997cites this paper
• Markers of Thrombosis and Fibrinolysis

  1997cites this paper
• Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes.

  1997cites this paper
• Low molecular weight heparin for acute ischemic heart disease.

  1997cites this paper
• Differential effect of a low-molecular-weight heparin (dalteparin) and unfractionated heparin on platelet interaction with the subendothelium under flow conditions.

  1997cites this paper
• Prothrombinase is protected from inactivation by tissue factor pathway inhibitor: competition between prothrombin and inhibitor.

  1997cites this paper
• Current Status of Activation Markers in lschemic Heart Disease: Markers of Coagulation Activation

  1997cites this paper
• Molecular basis for the resistance of fibrin-bound thrombin to inactivation by heparin/serpin complexes.

  1997cites this paper
• Subacute occlusion, bleeding complications, hospital stay and restenosis after Palmaz-Schatz coronary stenting under a new antithrombotic regimen.

  1996cites this paper
• Reversibility of Platelet Thrombosis In Vivo

  1996cites this paper
• Factor XIa Induced Activation of the Intrinsic Cascade In Vivo

  1996cites this paper
• The role of thrombin in coronary artery thrombosis.

  1996cites this paper
• Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa.

  1996cites this paper
• Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators.

  1996cites this paper
• Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial.

  1996cites this paper
• Effect of factor Xa inhibitors on thrombin formation and complement and neutrophil activation during in vitro extracorporeal circulation.

  1996cites this paper
• Inhibition of prothrombinase at macroscopic lipid membranes: competition between antithrombin and prothrombin.

  1995cites this paper
• Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction.

  1995cites this paper
• Primary Prevention of Coronary Arterial Thrombosis with the Factor Xa Inhibitor rTAP in a Canine Electrolytic Injury Model

  1995cites this paper
• Use of a direct thrombin inhibitor (argatroban) during pulse-spray thrombolysis in experimental thrombosis.

  1995cites this paper
• Factor Xa-factor Va complex assembles in two dimensions with unexpectedly high affinity: an experimental and theoretical approach.

  1995cites this paper
• Inhibition of Prothrombinase by Antithrombin-Heparin at a Macroscopic Surface

  1995cites this paper
• Management of venous thromboembolic disease. The impact of low-molecular-weight heparin.

  1995cites this paper
• Inhibition of Prothrombinose by Antithrombin-Hep orin of o Mocroscopic Surfoce

  1995cites this paper
• Novel antithrombotic strategies for the treatment of coronary artery thrombosis: A critical appraisal

  1995cites this paper
• Low molecular weight heparin (Fragmin) prevents early reocclusion following femoral artery thrombolysis with rt-PA in rabbits.

  1994cites this paper
• Specific Thrombin Inhibitors in Vivo

  1994cites this paper
• Activation markers of coagulation.

  1994cites this paper
• Low molecular weight heparin: a critical analysis of clinical trials.

  1994cites this paper
• Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty.

  1994cites this paper
• Inhibition of factor Xa-induced platelet aggregation by a selective thrombin inhibitor, argatroban.

  1994cites this paper
• Low molecular weight heparin: laboratory properties and clinical evaluation. A review.

  1994cites this paper
• Platelet membrane-mediated coagulation protease complex assembly.

  1994cites this paper
• Contribution of Plasma Proteinase Inhibitors to the Regulation of Activated Protein C in Plasma

  1993cites this paper
• Reocclusion following successful thrombolysis. Emerging concepts.

  1993cites this paper
• The challenge of maintaining coronary arterial patency with intravenous heparin following tissue plasminogen activator administration.

  1993cites this paper
• Laboratory markers of coagulation activation.

  1993cites this paper